指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

APASL ACLF北京立场声明:慢加急性肝衰竭重症监护管理的全球共识

A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper.
指南 / 共识 · Hepatol Int · 2026-07-30
一句话结论APASL发布104条立场声明,用AARC、CLIF-C ACLF、GIC评分指导ICU转入与治疗决策,积极处理诱因和感染,并详述肝、肾、脑器官支持。

慢加急性肝衰竭(ACLF)是慢性肝病患者的严重综合征,以快速多器官衰竭和高短期死亡率为特征,需要重症监护但此前缺乏标准化全球指南。APASL ACLF研究联盟组织109名专家,按GRADE系统制定推荐,经2025年3月北京APASL年会现场举手表决和后续匿名在线投票形成共识。共识共104条立场声明,关键推荐包括用AARC、CLIF-C ACLF、GIC等预后评分指导ICU转入和治疗决策,积极处理诱因及感染等并发症,详述肝、肾、脑衰竭的器官支持,倡导早期靶向抗生素和审慎液体管理,强调桥接治疗(血浆置换、人工肝系统)和营养支持的作用,并为肝移植提供患者选择和时机标准,尤其针对酒精相关ACLF。

要点

  • 共识推荐使用AARC、CLIF-C ACLF、GIC等预后评分指导ACLF患者的ICU转入和治疗决策。
  • 应积极处理ACLF的诱因及感染等并发症,倡导早期、靶向抗生素治疗和审慎的液体管理。
  • 共识详述肝、肾、脑衰竭的器官特异性支持,并强调桥接治疗(血浆置换、人工肝系统)和营养支持的作用。
  • 肝移植部分给出患者选择和时机标准,尤其针对酒精相关ACLF。
  • 部分推荐主要由不同大陆的数据支持,应结合本地情况解读。

适用人群与场景

  • 慢性肝病基础上发生慢加急性肝衰竭(ACLF)、需要重症监护的危重患者。
  • 肝移植相关推荐特别针对酒精相关ACLF患者。

诊断标准与关键阈值

  • 使用预后评分AARC、CLIF-C ACLF、GIC指导ICU转入和治疗决策。

处置流程与药物剂量

  • 积极处理ACLF的诱因或感染等并发症。
  • 对肝、肾、脑衰竭提供器官特异性支持。
  • 倡导早期、靶向抗生素治疗和审慎的液体管理。
  • 强调桥接治疗(血浆置换、人工肝系统)和营养支持的作用。
  • 肝移植方面提供患者选择和时机标准,尤其针对酒精相关ACLF。

研究设计与关键结果

  • APASL ACLF研究联盟组织109名专家,按GRADE系统制定推荐,经2025年3月北京APASL年会现场举手表决和后续匿名在线投票形成共识,共产生104条立场声明。

证据类型、等级与局限

  • 证据类型:指南/立场声明,推荐采用GRADE系统分级。
  • 局限:部分推荐主要由不同大陆的数据支持,应结合本地情况解读。

对床旁实践的改变

  • 作者认为,该立场声明为危重ACLF患者提供了全面、标准化的管理框架,整合多学科专业知识和当前证据,旨在优化诊疗、指导临床决策并改善这一高危人群的生存。
  • 作者认为,由于部分推荐主要由不同大陆的数据支持,应结合本地情况解读。

指南或共识出处

  • APASL ACLF Beijing Position Paper(APASL ACLF北京立场声明),由APASL ACLF研究联盟(AARC)制定,发表于Hepatol Int。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is a severe syndrome in patients with chronic liver disease, marked by rapid multi-organ failure and high short-term mortality. Managing ACLF requires intensive care, but standardized global guidelines were previously lacking. The APASL ACLF Research Consortium (AARC) developed this position paper to establish a unified, evidence-based consensus for its critical care management.

METHODS: A global collaboration of 109 experts employed a systematic methodology to address key aspects of ACLF care. Sections were drafted by specialist teams, with recommendations developed using the GRADE system. Draft statements underwent iterative review and refinement, followed by an expert panel consensus process consisting of open show-of-hands voting during the APASL Annual Conference in March 2025 in Beijing and a subsequent anonymous online voting round.

RESULTS: The consensus delivers 104 position statements. Key recommendations include using prognostic scores (AARC, CLIF-C ACLF, GIC) for ICU transfer and treatment decisions, and aggressively managing precipitating factors or complications like infections. It details organ-specific support for liver, kidney, and brain failure, advocating for early, targeted antibiotics and careful fluid management. The role of bridging therapies (plasma exchange, artificial liver systems) and nutritional support is emphasized. For transplantation, the guidelines provide criteria for patient selection and timing, particularly for alcohol-related ACLF.

CONCLUSIONS: The APASL ACLF Beijing Position Paper provides a comprehensive, standardized framework for managing critically sick ACLF patients. Integrating multidisciplinary expertise and current evidence, these guidelines aim to optimize care, inform clinical decisions, and improve survival for this high-risk population. As a few recommendations are supported predominantly by data from different continents, they should therefore be interpreted in local contexts.

来源:Hepatol Int,查看原文。版权归原作者所有。

参考来源

  1. Chen T, Choudhury A, Liu W, et al. A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper. Hepatol Int. 2026. PMID: 42533257. doi:10.1007/s12072-026-11116-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。